Range Low Price High Price Comment
30 days $27.00 $36.72 Thursday, 28th Mar 2024 ARWR stock ended at $28.60. This is 0.348% less than the trading day before Wednesday, 27th Mar 2024. During the day the stock fluctuated 3.44% from a day low at $28.10 to a day high of $29.07.
90 days $27.00 $39.83
52 weeks $20.67 $42.48

Historical Arrowhead Research Corporation prices

Date Open High Low Close Volume
2024-02-22 $29.27 $30.84 $28.50 $30.20 1 210 966
2024-02-21 $29.22 $29.61 $28.94 $29.18 858 187
2024-02-20 $29.05 $29.56 $28.74 $29.22 995 844
2024-02-16 $29.13 $30.12 $28.53 $29.48 1 046 153
2024-02-15 $29.77 $30.39 $29.46 $29.57 1 197 353
2024-02-14 $30.28 $30.36 $29.30 $29.63 1 033 711
2024-02-13 $31.23 $31.23 $29.41 $29.92 1 726 142
2024-02-12 $32.56 $33.02 $31.47 $32.26 1 148 189
2024-02-09 $30.93 $32.68 $30.62 $32.56 1 452 679
2024-02-08 $31.93 $32.57 $30.77 $30.85 1 733 027
2024-02-07 $31.75 $31.92 $29.50 $31.65 3 217 926
2024-02-06 $31.93 $33.28 $31.55 $33.20 1 052 109
2024-02-05 $31.23 $32.47 $30.54 $32.02 948 624
2024-02-02 $31.52 $32.16 $30.65 $31.96 855 622
2024-02-01 $32.25 $32.37 $31.32 $32.19 836 214
2024-01-31 $32.91 $33.36 $31.79 $32.10 837 959
2024-01-30 $34.19 $34.39 $32.95 $33.01 594 348
2024-01-29 $32.62 $34.46 $32.00 $34.40 740 010
2024-01-26 $33.67 $33.77 $32.56 $32.75 519 658
2024-01-25 $33.00 $33.87 $32.86 $33.42 659 955
2024-01-24 $34.58 $34.95 $32.78 $32.81 811 830
2024-01-23 $33.89 $34.50 $33.42 $34.29 1 210 069
2024-01-22 $33.83 $33.91 $32.58 $33.19 1 371 871
2024-01-19 $33.32 $34.15 $32.90 $33.75 996 047
2024-01-18 $34.39 $34.39 $32.71 $33.16 1 478 395
Click to get the best stock tips daily for free!

About Arrowhead Research Corporation

Arrowhead Research Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P... ARWR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT